# Entecavir to TAF Switch

> **NCT03489239** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Thomas Jefferson University** · enrollment: 27 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** Tenofovir Alafenamide

## Key facts

- **NCT ID:** NCT03489239
- **Lead sponsor:** Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-11-16
- **Primary completion:** 2020-08-15
- **Final completion:** 2020-09-16
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2020-06-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03489239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03489239, "Entecavir to TAF Switch". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03489239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*